12/09/2019 | Press release | Distributed by Public on 12/09/2019 07:49
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- BioInformatics Inc., the leading research and advisory firm serving the life science tools market, recognized Fluidigm (NASDAQ:FLDM) with the Gold Award for the Best New Product in Cell Biology for the Maxpar® Direct™ Immune Profiling System. The Maxpar Direct Immune Profiling System empowers researchers to easily quantify 37 different immune cell populations from human peripheral blood mononuclear cells (PBMC) and whole blood using CyTOF® technology.
Designed as people's choice awards, the Life Science Industry Awards (LSIA) have been a tradition in the life science industry for more than 15 years. The Best New Product in Cell Biology Award recognizes companies for commercializing innovative solutions to streamline and automate workflows for greater throughput, more reliable results and faster discoveries. Recipients are selected based on responses from thousands of scientists who are members of The Science Advisory Board, the world's largest market research panel of scientific customers. Winners are chosen based on both the number of votes received and the depth of the company's customer loyalty and satisfaction.
The Maxpar Direct Immune Profiling System includes a 30-marker antibody panel developed with input from expert academic and biopharma immunologists. Provided in a dry format in ready-to-use assay tubes, it enables researchers to easily analyze immune phenotypes from PBMC or directly from whole blood using a simple single-tube workflow. Designed for flexibility, the Maxpar® Direct™ Immune Profiling Assay™ allows researchers to easily add new antibodies to the panel to support specific study goals. Automated results reporting and quality assessment is completed in just five minutes using the Maxpar Pathsetter™ software.
'We are excited to recognize Fluidigm with the Best New Product in Cell Biology Award,' said Craig Overpeck, CEO of BioInformatics Inc. 'The Maxpar Direct Immune Profiling System provides a revolutionary new step forward in highly multiplexed cytometry, providing researchers with a simple, easy to use workflow to comprehensively profile immune cell phenotypes. We have been impressed by how this product has rapidly gained significant interest within our translational research community, having potential to transform our understanding of the immune system and accelerate therapeutic development for many years to come.'
'Receiving this innovation award is a high honor, especially in light of the competition we face in this category. It builds upon the recognition we received by the same community last year as the Company to Watch in 2019,' said Chris Linthwaite, President and CEO of Fluidigm. 'This immune profiling solution holds the potential to become an industry‑standard approach and is a fast‑growing reagent in mass cytometry, serving the needs of cancer centers, academic medical research and pharmaceutical companies. We are excited by the potential for this product in the years ahead.'
About Bioinformatics Inc.
BioInformatics Inc., now part of Science and Medicine Group, is the premier research and advisory firm serving the life science, clinical diagnostics, and analytical instrument industries. By leveraging our expert network of more than 50,000 life scientists, the company has supported more than 500 companies in creating insights that lead to better business decisions. Offerings include assessing the size and attractiveness of scientific markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning.
Fluidigm (NASDAQ:FLDM) is an industry-leading biotechnology tools provider with a vision to improve life through comprehensive health insight. We focus on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com.
Fluidigm, the Fluidigm logo, CyTOF, Direct, Immune Profiling Assay, Maxpar and Pathsetter are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding prospects for Fluidigm products. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new products; potential product performance and quality issues; intellectual property risks; and competition. Information on these and additional risks and uncertainties and other information affecting Fluidigm's business and operating results is contained in Fluidigm's Annual Report on Form 10-K for the year ended December 31, 2018, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.
Content Marketing Associate
703 778 3080 x37
Media: Michaeline Bunting
Senior Director, Marketing
650 737 4190
Vice President, Investor Relations
650 416 7423
Source: Fluidigm Corporation